Wed. Oct 5th, 2022
Biocon Biologics bets on insulin glargine ramp-up as it looks overcome a tepid Q2 Despite the operational challenges posed by Covid-19, Biocon’s biologics division says it is committed to achieve its $1 billion revenue target by the end of FY22.